177 related articles for article (PubMed ID: 32312633)
1. Efficacy and Safety of the Modified EPOCH Regimen (Etoposide, Vincristine, Doxorubicin, Carboplatin, and Prednisolone) for Adult T-cell Leukemia/Lymphoma: A Multicenter Retrospective Study.
Tsukamoto Y; Kiyasu J; Choi I; Kozuru M; Uike N; Utsunomiya H; Hirata A; Fujioka E; Ohno H; Nakashima E; Nakashima Y; Miyashita K; Tachikawa Y; Narazaki T; Tsuda M; Haji S; Takamatsu A; Tanaka E; Goto T; Takatsuki H; Oyama M; Muta H; Yagi Y; Ikeda M; Matsushima T; Yufu Y; Suehiro Y
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e445-e453. PubMed ID: 32312633
[TBL] [Abstract][Full Text] [Related]
2. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
[TBL] [Abstract][Full Text] [Related]
3. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Bartlett NL; Wilson WH; Jung SH; Hsi ED; Maurer MJ; Pederson LD; Polley MC; Pitcher BN; Cheson BD; Kahl BS; Friedberg JW; Staudt LM; Wagner-Johnston ND; Blum KA; Abramson JS; Reddy NM; Winter JN; Chang JE; Gopal AK; Chadburn A; Mathew S; Fisher RI; Richards KL; Schöder H; Zelenetz AD; Leonard JP
J Clin Oncol; 2019 Jul; 37(21):1790-1799. PubMed ID: 30939090
[TBL] [Abstract][Full Text] [Related]
4. Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).
Ramos JC; Sparano JA; Rudek MA; Moore PC; Cesarman E; Reid EG; Henry D; Ratner L; Aboulafia D; Lee JY; Ambinder RF; Mitsuyasu R; Noy A
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):180-190.e2. PubMed ID: 29426719
[TBL] [Abstract][Full Text] [Related]
5. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma.
Wilder DD; Ogden JL; Jain VK
Clin Lymphoma; 2001 Mar; 1(4):285-92. PubMed ID: 11707843
[TBL] [Abstract][Full Text] [Related]
6. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
[TBL] [Abstract][Full Text] [Related]
7. Mogamulizumab Plus EPOCH Therapy for Patients With Newly Diagnosed Aggressive Adult T-cell Leukemia/lymphoma.
Jo T; Matsuzaka K; Shioya H; Tominaga H; Sakai T; Kaneko Y; Hayashi S; Matsuo M; Taguchi J; Abe K; Shigematsu K; Kubota-Koketsu R
Anticancer Res; 2020 Sep; 40(9):5237-5243. PubMed ID: 32878812
[TBL] [Abstract][Full Text] [Related]
8. Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma.
Ratner L; Rauch D; Abel H; Caruso B; Noy A; Barta SK; Parekh S; Ramos JC; Ambinder R; Phillips A; Harding J; Baydoun HH; Cheng X; Jacobson S
Blood Cancer J; 2016 Mar; 6(3):e408. PubMed ID: 27015285
[No Abstract] [Full Text] [Related]
9. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
[TBL] [Abstract][Full Text] [Related]
10. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
11. Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States.
Roe C; Komrokji R; Zhang L; Price S; Sokol L
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S191-4. PubMed ID: 27521318
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
13. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
[TBL] [Abstract][Full Text] [Related]
14. Clinical Features and Treatment Outcomes of 81 Patients with Aggressive Type Adult T-cell Leukemia-lymphoma at a Single Institution over a 7-year Period (2006-2012).
Kawano N; Yoshida S; Kuriyama T; Tahara Y; Yamashita K; Nagahiro Y; Kawano J; Koketsu H; Toyofuku A; Manabe T; Beppu K; Ono N; Himeji D; Yokota-Ikeda N; Inoue S; Ochiai H; Sonoda KH; Shimoda K; Ishikawa F; Ueda A
Intern Med; 2015; 54(12):1489-98. PubMed ID: 26073237
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcome of elderly patients with aggressive adult T cell leukemia-lymphoma: Nagasaki University Hospital experience.
Makiyama J; Imaizumi Y; Tsushima H; Taniguchi H; Moriwaki Y; Sawayama Y; Imanishi D; Taguchi J; Hata T; Tsukasaki K; Miyazaki Y
Int J Hematol; 2014 Nov; 100(5):464-72. PubMed ID: 25209605
[TBL] [Abstract][Full Text] [Related]
16. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
17. EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma.
Toriyama E; Imaizumi Y; Taniguchi H; Taguchi J; Nakashima J; Itonaga H; Sato S; Ando K; Sawayama Y; Hata T; Fukushima T; Miyazaki Y
Int J Hematol; 2018 Aug; 108(2):167-175. PubMed ID: 29651666
[TBL] [Abstract][Full Text] [Related]
18. Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.
Alduaij A; Butera JN; Treaba D; Castillo J
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):480-3. PubMed ID: 21156467
[TBL] [Abstract][Full Text] [Related]
19. High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma.
Hyun SY; Cheong JW; Kim SJ; Min YH; Yang DH; Ahn JS; Lee WS; Ryoo HM; Do YR; Lee HS; Lee JH; Oh SY; Suh C; Yhim HY; Kim JS
Biol Blood Marrow Transplant; 2014 Jan; 20(1):73-9. PubMed ID: 24141009
[TBL] [Abstract][Full Text] [Related]
20. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Maeda Y; Nishimori H; Yoshida I; Hiramatsu Y; Uno M; Masaki Y; Sunami K; Masunari T; Nawa Y; Yamane H; Gomyo H; Takahashi T; Yano T; Matsuo K; Ohshima K; Nakamura S; Yoshino T; Tanimoto M
Haematologica; 2017 Dec; 102(12):2097-2103. PubMed ID: 28971899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
